



Q1 2020 RESULTS



“ I am proud of the way Sanofi employees have responded to the immense challenges of the COVID-19 pandemic. They continue to put patients first while embracing and delivering on the new Company strategy. ”

PAUL HUDSON

CHIEF EXECUTIVE OFFICER, SANOFI

COMPANY SALES & BUSINESS EPS*

Q1 2020 SALES*
€8,973M
+6.6% (+6.9%)

Q1 2020 BUSINESS EPS*
€1.63
+15.6% (+15.6%)

*Growth rates are expressed at constant exchange rates (CER). Growth rates in parentheses are expressed on a reported basis.

SALES BY GLOBAL BUSINESS UNIT


€2,695M
Specialty Care


€909M
Vaccines


€4,069M
General Medicines


€1,300M
Consumer Healthcare

SALES BY GEOGRAPHY



SANOFI AT FOREFRONT OF FIGHT AGAINST COVID-19

 <p>Developing vaccines and treatments 3 collaborations to develop novel COVID-19 vaccines 2 existing treatments evaluated 1 partnership to develop smartphone-based self-testing solution</p>	 <p>Supporting patients, healthcare workers and health authorities Commitment to donate 100 million doses of anti-viral treatment</p>	 <p>Ensuring continuous manufacturing and delivery of essential medicines and vaccines 20,000 employees working every day in all industrial sites 100% of manufacturing sites operational</p>
--	---	---

R&D HIGHLIGHTS

<p>87 projects in development, including 35 new molecular entities & additional indications</p> 	<p>39 projects in Phase 3 or submitted for approval</p> 
--	--

For further information on Q1 2020 results and definitions of financial indicators, please refer to the press release issued on April 24, 2020 at:

<https://www.sanofi.com/en/investors>



Sanofi.com

Sanofi.us

